Online citations, reference lists, and bibliographies.
← Back to Search

Fifteen-Year Experience In Treating Blepharospasm With Botox Or Dysport: Same Toxin, Two Drugs

A. R. Bentivoglio, A. Fasano, T. Ialongo, F. Soleti, S. Lo Fermo, A. Albanese
Published 2009 · Psychology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Objectives To compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years. Methods We have reviewed the clinical charts of 128 patients with BS who received botulinum neurotoxin (BoNT) in 1341 treatments (Botox in 1009, Dysport in 332) over the last 15 years. Results Mean dose per session was 34U ± 15 for Botox and 152U ± 54 for Dysport. Mean latency of clinical effect was 4.5 ± 4.6 days for Botox and 5.0 ± 5.7 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher for Dysport than Botox: 80.1 ± 36.3 and 66.2 ± 39.8 days, respectively (P < 0.01). In a six-point scale (0: no efficacy, 6: remission of BS), the mean efficacy of both treatments was 3.60 ± 1.3; 3.51 ± 1.4 (Botox) and 3.85 ± 1.2 (Dysport), P < 0.01. The doses of Botox (β = 0.40) and Dysport (β = 0.16) were significantly increased over time. Side effects occurred in 325 out of 1341 treatments (24.2%): 21.8% of the patients who had received Botox, and in 31.6% of those who had received Dysport (P < 0.01). Conclusions Both brands are effective and safe in treating blepharospasm; efficacy is long lasting. The differences in outcome and side effects suggest that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.
This paper references
10.1007/PL00007849
Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm
R. Çakmur (2002)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1185/030079905X36396
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm
K. Bihari (2005)
10.1136/jnnp.53.8.633
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
J. Jankovic (1990)
10.1016/S0161-6420(86)33520-6
Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm.
C. Burns (1986)
Effects of repeated botulinum toxin injections on orbicularis oculi muscle.
G. Borodic (1992)
10.1016/S0161-6420(95)30757-9
Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
J. Ainsworth (1995)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.3109/01658109209058127
'Ping-pong' gaze
Borodic Ge (1992)
Botulinum toxin injection of eye muscles to correct strabismus.
A. B. Scott (1981)
10.1111/j.1468-1331.2006.01537.x
A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS‐ES Task Force
Alberto Albanese (2006)
10.1017/S0317167100026159
Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
J. Carruthers (1987)
10.1097/00002341-198601050-00003
Orbicularis muscle pathology after botulinum toxin injection.
T. Wojno (1986)
10.1136/jnnp.51.6.767
Blepharospasm: a review of 264 patients.
F. Grandas (1988)
10.1136/jnnp.73.5.604
Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia
D. Dressler (2002)
10.1002/mds.10252
Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period
G. Hsiung (2002)
10.1016/J.OPHTHA.2006.03.055
Supramaximal doses of botulinum toxin for refractory blepharospasm.
R. L. Levy (2006)
Blepharospasm: demographic and clinical survey of 250 patients.
J. Jankovic (1984)
10.1017/S0317167100027748
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
S. Kraft (1988)
10.33588/rn.3806.2003433
Evolución de la dosis de toxina botulínica tipo A en distonías craneocervicales: Estudio comparativo a lo largo de ocho años
Amaya Echeverría Urabayen (2004)
10.1016/S0161-6420(87)33338-X
Effectiveness of botulinum toxin therapy for essential blepharospasm.
P. Engstrom (1987)
10.1002/MUS.880180708
Five‐year experience in the treatment of focal movement disorders with low‐dose dysportTM botulinum toxin
P. V. D. van den Bergh (1995)
10.1002/mds.20376
Long‐term botulinum toxin efficacy, safety, and immunogenicity
Nicte I. Mejia (2005)
Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study.
J. Taylor (1991)
Double - blind controlled study of botulinum toxin for blepharospasm
S Fahn (1985)
10.1111/j.1442-9071.2006.01236.x
Use of high‐dose botulinum A toxin in benign essential blepharospasm: is too high too much?
A. L. Pang (2006)
10.1002/mds.20066
Clinical comparability of marketed formulations of botulinum toxin
C. Sampaio (2004)
10.1016/S0161-6420(86)33641-8
Treatment of facial spasm with botulinum toxin. An interim report.
B. Frueh (1986)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
[Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study].
A Echeverría Urabayen (2004)
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Niiligens (1997)
Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
A. Thussu (1999)
10.1016/0022-510X(71)90129-8
An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse.
L. Duchen (1971)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.1159/000153521
The use of incompletely linked markers in genetic counseling: accuracy versus linkage.
M. A. Asmussen (1985)
10.1002/14651858.CD004900.PUB2
Botulinum toxin type A therapy for blepharospasm.
J. Costa (2005)
The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.
K. Kessler (1997)
Les convulsions de la face: une forme clinique de convulsions faciales, bilaterale et mediane
H Meige (1910)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.1002/MDS.870120116
The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A
K. Kessler (1997)
10.1185/030079904125003962
Safety of botulinum toxin type A: a systematic review and meta-analysis
M. Naumann (2004)
10.1136/bmj.290.6485.1857
Effect of treatment with botulinum toxin on neurogenic blepharospasm.
J. Elston (1985)
10.1590/S0004-282X2005000200006
Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
L. Silveira-Moriyama (2005)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1136/BJO.75.12.737
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
J. Mauriello (1991)
10.1002/MDS.870090106
Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections
G. Borodic (1994)
10.1212/WNL.35.1.73
Validity and reliability of a rating scale for the primary torsion dystonias
R. Burke (1985)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.3346/JKMS.1993.8.5.334
Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
Y. C. Park (1993)
10.1159/000116805
Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm.
Alberto Albanese (1992)
10.1007/PL00004951
Botulinum A toxins: units versus units
K. Wohlfarth (1997)
10.1097/00002826-198610000-00002
Botulinum injection therapy for blepharospasm: a review and report of 75 patients.
D. Cohen (1986)
10.1016/0041-0101(96)00070-0
Therapeutic botulinum type A toxin: factors affecting potency.
K. Mclellan (1996)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
10.29819/ANT.200506.0003
Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm.
C. Tsai (2005)
10.1007/BF00941758
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Nüβgens (2004)
Five year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve
P Van den Bergh (1995)
10.1111/j.1755-3768.1990.tb01933.x
Long‐term treatment of involuntary facial spasms using botulinum toxin
P. Ruusuvaara (1990)
10.1097/00002341-198601060-00010
The Use of Botulinum Toxin in the Medical Management of Benign Essential Blepharospasm
K. I. Perman (1986)
10.1097/00041327-199712000-00062
Treatment Selections of 239 Patients With Blepharospasm and Meige Syndrome Over 11 Years
J. Mauriello (1997)
10.1007/BF00839203
The management of blepharospasm and hemifacial spasm
J. Elston (2004)



This paper is referenced by
10.1007/978-1-4939-0261-3
Clinical Applications of Botulinum Neurotoxin
K. Foster (2014)
10.1007/s00415-019-09581-w
Treatment of blepharospasm and Meige’s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice
A. Jochim (2019)
EFNS guidelines on diagnosis and treatment of primary dystonias
A. Albanesea (2010)
10.1097/IIO.0000000000000207
Benign Essential Blepharospasm: What We Know and What We Don’t
C. J. Hwang (2018)
10.1055/s-0031-1299095
[Botulinum toxin in clinical neurology].
J. Wissel (2012)
10.1007/978-1-4939-0261-3_2
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
A. Pickett (2014)
10.1001/jama.2010.1937
Terminology for preparations of botulinum neurotoxins: what a difference a name makes.
A. Albanese (2011)
10.2147/TCRM.S99239
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Avram Fraint (2016)
10.5152/JAREM.2016.1061
OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®) in Treating Essential Blepharospasm: Long Term Results
Fadime Nuhoğlu (2016)
10.1007/978-3-662-48468-5_6
Patterned or Repetitive Movements and/or Abnormal Posturing
D. Martino (2016)
Terminology for Preparations of Botulinum Neurotoxins
Alberto Albanese (2011)
10.1111/ceo.12165
Long‐term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm
Osama H. Ababneh (2014)
10.1212/WNL.0000000000002560
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache
D. Simpson (2016)
10.4067/S0717-92272013000200005
Consenso chileno sobre Abobotulinumtoxina A (Dysport®): indicaciones, técnicas
P. Chaná-Cuevas (2013)
10.3109/00207454.2010.539306
New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia
A. Pickett (2011)
10.7916/D8CJ8CVR
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm
K. Dashtipour (2015)
10.1016/j.toxicon.2014.07.009
Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.
Juan Ramirez-Castaneda (2014)
10.1007/s12640-017-9737-6
Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia
A. R. Bentivoglio (2017)
10.1007/978-3-030-50691-9_4
Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine
D. Vijayakumar (2020)
10.3390/toxins12050332
FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
Lauren L Spiegel (2020)
10.2147/OPTH.S24394
Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data
Andy Pickett (2011)
10.1111/ene.14258
An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm
M. Osaki (2020)
10.1111/j.1468-1331.2010.03042.x
EFNS guidelines on diagnosis and treatment of primary dystonias
Alberto Albanese (2011)
10.1007/s00702-014-1278-z
Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®
K. Kollewe (2014)
10.3390/toxins5020249
Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia
Juan Ramirez-Castaneda (2013)
10.1002/9781444328394.CH12
Diagnosis and Treatment of Primary (Idiopathic) Dystonia
Alberto Albanese (2010)
10.1007/978-1-4939-0261-3_3
Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders
A. Guidubaldi (2014)
10.1002/mds.23658
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial
J. Jankovic (2011)
10.1177/1120672120925630
The good toxin: 10 years of experience with botulinum toxin A in the treatment of benign essential blepharospasm.
K. K. Lai (2020)
10.1212/01.CON.0000436154.08791.67
Dystonia
Francesca Morgante (2013)
OnabotulinumtoxinA ( Botox ® ) and AbobotulinumtoxinA ( Dysport ® )
Fatma Esin Özdemir (2016)
10.1002/9781444346183.ch8
8. Primary Dystonias
A. Elia (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar